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nloaded frDeconstruction of an African folk medicine uncovers a
novel molecular strategy for therapeutic potassium
channel activation
Angele M. De Silva*, Rían W. Manville*†, Geoffrey W. Abbott†
A third of the global population relies heavily upon traditional or folk medicines, such as the African shrub
Mallotus oppositifolius. Here, we used pharmacological screening and electrophysiological analysis in combina-
tion with in silico docking and site-directed mutagenesis to elucidate the effects of M. oppositifolius constituents
on KCNQ1, a ubiquitous and influential cardiac and epithelial voltage-gated potassium (Kv) channel. Two com-
ponents of the M. oppositifolius leaf extract, mallotoxin (MTX) and 3-ethyl-2-hydroxy-2-cyclopenten-1-one
(CPT1), augmented KCNQ1 current by negative shifting its voltage dependence of activation. MTX was also
highly effective at augmenting currents generated by KCNQ1 in complexes with native partners KCNE1 or
SMIT1; conversely, MTX inhibited KCNQ1-KCNE3 channels. MTX and CPT1 activated KCNQ1 by hydrogen
bonding to the foot of the voltage sensor, a previously unidentified drug site which we also find to be essential
for MTX activation of the related KCNQ2/3 channel. The findings elucidate the molecular mechanistic basis for
modulation by a widely used folk medicine of an important human Kv channel and uncover novel molecular
approaches for therapeutic modulation of potassium channel activity.h
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Essential modern medicines are estimated by the World Health Orga-
nization to be readily available to two-thirds of the global population,
with the remainder relying on traditional or folk remedies to treatmany
serious illnesses and ailments (1). Extracts from the leaf of Mallotus
oppositifolius (Fig. 1A), a shrub commonly found in Ghana andNigeria
(2, 3), reportedly have anti-inflammatory and antimicrobial properties,
and are used to treat epilepsy, diabetes, headaches, pain, parasitic eye
infections, kidney infections, and paralysis (3, 4).
One of the primary components of M. oppositifolius leaf extract,
mallotoxin (MTX; also known as rottlerin), was previously reported to
activate BK, hERG, and KCNQ1 potassium channels (5–7). However,
the binding sites, and therefore direct versus indirect mechanism for
this activation, have not previously been elucidated. Furthermore, the
potential effects of other Mallotus components on BK, hERG, and
KCNQ1 have not been elucidated. Human KCNQ1 is ubiquitously
expressed in tissues including the heart, gastrointestinal tract, thyroid,
pancreas, pituitary gland, choroid plexus, kidney, and inner ear (8)
and is highly influential in human health. KCNQ1 gene variants have
been linked to cardiac arrhythmias (8, 9), deafness (10), diabetes (11–13),
anemia, gastric hyperplasia, and gastric tumors (14, 15). Kcnq1 germ
line deletion in mice also causes thyroid dysfunction (16) and its phar-
macological disruption results in renal abnormalities (17). Kv channels
such as KCNQ1 are composed of tetramers of a subunits each containing
six transmembrane segments (S1 to S6), split into a voltage-sensing
domain (VSD) (S1 to S4) and a pore module (S5 and S6) (Fig. 1B).
KCNQ1 is versatile, not only serving physiological roles such as re-
polarizing excitable cells including cardiac myocytes but also pro-
viding a K+ recycling pathway in nonexcitable, polarized epithelial
cells such as parietal cells, facilitating gastric acid secretion. This ver-
satility is possible because KCNQ1 forms complexes with single trans-membrane domain KCNE ancillary (b) subunits, resulting in channels
with diverse functional and pharmacological characteristics (8).
Because the ubiquity and importance of KCNQ1 make it a strong
candidate for explaining the underlying mechanistic basis of the thera-
peutic effects of Mallotus, we screened leaf extract components for
KCNQ1 activity. We found that two components, MTX and 3-ethyl-
2-hydroxy-2-cyclopenten-1-one (CPT1), activate KCNQ1 channels by
an unexpected, novel mechanism—binding to a novel drug site at the
foot of the voltage sensor.RESULTS
M. oppositifolius leaf extract components activate KCNQ1
We screened 10 previously identified M. oppositifolius leaf extract
components (Fig. 1C) (18) by quantifying their effects on KCNQ1
tail currents at −30 mV immediately following channel activation at
voltages between −80 and +40 mV using two electrode voltage clamp
of KCNQ1 heterologously expressed in Xenopus laevis oocytes. We
found that 2 of the 10 compounds studied, CPT1 and MTX, negatively
shifted the voltage dependence of KCNQ1 activation, thus augmenting
currents (Fig. 1C). MTX was the most potent and efficacious KCNQ1
activator. MTX activation of KCNQ1 was voltage dependent, with
greater efficacy observed at hyperpolarized voltages (Fig. 1, D and E).
CPT1 (100 mM) negatively shifted the voltage dependence of KCNQ1
activation by −5 mV. The other compounds had no effect at 30 or
100 mM on KCNQ1 current magnitude or other properties (Fig. 1, D
and E, and figs. S1 and S2).
At −40 mV, 30 mM MTX increased KCNQ1 current 5.4-fold
(Fig. 2, A and B); the activation EC50 (median effective concentration)
was 9.9 ± 0.4 mM(Fig. 2B). At 100 mM,MTX caused a −27mVnegative
shift in the voltage dependence of KCNQ1 activation, and the dose re-
sponse for the DV0.5 activation was 9.4 ± 0.1 mMMTX (Fig. 2C). MTX
speeded KCNQ1 activation and slowed its deactivation, suggesting sta-
bilization of theKCNQ1open state and destabilization of its closed state
(fig. S2D). CPT1 was slightly less efficacious but 100-fold more potent,
increasing KCNQ1 current 2.7-fold at −60 mV (100 mM) (Fig. 2, D1 of 9
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 Fig. 1. Two components ofM. oppositifolius leaf extract activate KCNQ1 channels. (A) M. oppositifolius (Geiseler) Mull. Arg. Photo by E. Bidault. Source: Tropicos.org.
Missouri Botanical Garden (http://tropicos.org/Image/100521734). (B) KCNQ1 topology (two of four subunits shown). (C) Structure and electrostatic surface potential
(blue, positive; green, neutral; red, negative) of M. oppositifolius leaf extract components. (D) Averaged KCNQ1 current traces in response to voltage protocol (upper
inset) when bathed in the absence (control) or presence of M. oppositifolius leaf extract components (n = 5 to 8). Dashed line indicates zero current level in these and
all following current traces. (E) Mean effects of leaf extract components [as in (D); n = 5 to 8] on KCNQ1 raw tail currents at −30 mV after prepulses as indicated (left);
G/Gmax calculated from tail currents (right). Error bars indicate SEM. Ctrl, control.De Silva et al., Sci. Adv. 2018;4 : eaav0824 14 November 2018 2 of 9
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 and E); the activation EC50 was 0.09 ± 0.6 mM at −60 mV (Fig. 2E).
CPT1 only shifted KCNQ1 activation V0.5 by −6.4 mV, partly be-
cause its effects were less voltage dependent than those of MTX;
the EC50 for the DV0.5 activation was 0.1 ± 0.8 mM CPT1 (Fig. 2F).
CPT1 had less dramatic effects than MTX on KCNQ1 gating ki-
netics, yet still induced a statistically significant speeding of activa-
tion and slowing of deactivation (fig. S1D).
Interacting proteins alter KCNQ1 efficacy and sensitivity
to MTX
KCNQ1 is regulated extensively by KCNE b subunits in vivo. In hu-
man ventricular myocardium, KCNQ1-KCNE1 channel complexes
generate the slow-activating, noninactivating IKs current that is impor-
tant for cardiac myocyte repolarization; the same channel complex is
required for K+ secretion into the endolymph of the inner ear (19).
KCNE1 has been shown previously to both sensitize (20) and de-
sensitize (21) KCNQ1 to various synthetic compounds. Here, MTX
(30 mM) strongly augmented KCNQ1-KCNE1 currents across the
voltage range tested and shifted the V0.5 of activation by −45 mV,
compared to the −27 mV shift in KCNQ1 activation voltage de-
pendence induced by 30 mM MTX (Fig. 3, A and B, fig. S3). This,
combined with the slowing of deactivation produced by MTX, in-
duced a constitutively active component to the KCNQ1-KCNE1 cur-
rent (because the channels did not close to any great extent between
depolarizing pulses) (Fig. 3, A, C, and D), an effect we did not observe
for MTX with homomeric KCNQ1 (Fig. 1D). However, the MTX
EC50 for KCNQ1-KCNE1 (27.9 ± 0.3 mM; Fig. 3E) was threefold high-
er than that of KCNQ1 (9.9 ± 0.4 mM; Fig. 2B).
In contrast to KCNE1, KCNE3 converts KCNQ1 to a constitutively
active channel by locking open the VSD, which in turn holds open the
pore (22, 23). KCNQ1-KCNE3 channels are thought to be important
for regulating cAMP (adenosine 3′,5′-monophosphate)–stimulated
chloride secretion in the intestinal epithelia (24). KCNQ1-KCNE3
channels were moderately inhibited, not activated, by 30 mM MTX
across the voltage range studied (Fig. 3, F and G). KCNE4 is the mostDe Silva et al., Sci. Adv. 2018;4 : eaav0824 14 November 2018highly expressed KCNE subunit in human heart (25, 26). In mouse
heart, KCNE4 regulates Kv4 and Kv1.5 channels (27). KCNE4 strongly
inhibits KCNQ1 activity in heterologous expression studies (28, 29), al-
though the role of this regulation in vivo is not known. MTX (30 mM)
induced minor augmentation of KCNQ1-KCNE4 activity; therefore,
it did not substantively interfere with KCNE4 inhibition of KCNQ1
(Fig. 3, H and I).
KCNQ1 can also form complexes with the Na+-coupled myo-
inositol transporter SMIT1 (encoded by SLC5A3). Complex formation
results in reciprocal regulation of both KCNQ1 and SMIT1, and
KCNQ1-SMIT1 complexes in the choroid plexus epitheliumare impor-
tant for regulating cerebrospinal fluidmyo-inositol content (8).We pre-
viously showed that SMIT1 interacts with the KCNQ1 pore module,
altering its conformation and, thus, relative ion permeability (Fig. 4,
A and B) (30). Here, MTX (30 mM) negative shifted the voltage depen-
dence of KCNQ1-SMIT1 activation by a similar extent to effects on
KCNQ1 alone (Fig. 4, C to E, and fig. S4). The potency and efficacy
of MTX on KCNQ1-SMIT1 were similar to those for KCNQ1 (Fig. 4F).
However, MTX effects superimposed on those of SMIT1, which also
negative shifts the voltage dependence of KCNQ1 activation; thus,
KCNQ1-SMIT1 complexes with MTX were much more active at hy-
perpolarized membrane potentials than KCNQ1 channels with MTX
(Fig. 4G). In summary, the data predict thatMTXwould be particularly
effective at augmenting activity of KCNQ1 in vivo when in complexes
with KCNE1 or SMIT1.
MTX influences pore conformation and is still active in high
extracellular K+
MTX effects onKCNQ1were preserved in high (50mM) extracellular
K+ (fig. S5, A and B), leading us to hypothesize that MTX might be
positioned outside the pore, versus an internal pore location forMTX,
a position inwhich high extracellularK+would be expected to knock it
off. UCL2077 is a subtype-specific KCNQ open-channel blocker (31)
thought to bind to and stabilize KCNQ1 S6 in the closed state without
affecting S4 movement (32). UCL2077 also enhances KCNQ3 currentsFig. 2. MTX and CPT1 each activate KCNQ1 channels. All error bars indicate SEM. (A) Voltage dependence of KCNQ1 current fold increase by MTX (30 mM), plotted
from traces as in Fig. 1 (n = 7). (B) Dose response of KCNQ1 channels at −40 mV for MTX (calculated EC50 = 10 mM; n = 7). (C) Dose response for mean DV0.5 of activation
induced by MTX for KCNQ1 (n = 7). (D) Voltage dependence of KCNQ1 current fold increase by CPT1 (100 mM), plotted from traces as in Fig. 1 (n = 4 to 6). (E) Dose
response of KCNQ1 channels at −60 mV for CPT1 (n = 4 to 6). (F) Dose response for mean DV0.5 of activation induced by CPT1 for KCNQ1 (n = 4 to 6).3 of 9
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 at negative membrane potentials, an effect that requires the KCNQ3
S5 tryptophanW265 (31). Here, we found that MTX (30 mM) was in-
effective at rescuing KCNQ1 from inhibition by UCL2077 at positive
voltages, but still augmented KCNQ1 current at hyperpolarized volt-
ages despite the presence of UCL2077 (10 mM) (fig. S5, C and D). This
bimodal effect was reminiscent of the reported effect of UCL2077 on
KCNQ3 via its W265; however, KCNQ1 lacks W265 and is generally
insensitive to the augmenting effects of various agonists that augment
some or all of KCNQ2-5 isoforms via the W265 equivalent (33–35).
This led us to speculate that MTX might sit in a binding pocket on
KCNQ1 outside the pore but close enough to S5 to influence pore con-
formation and/or voltage sensitivity.
MTX and CPT1 bind to KCNQ1-R243 at the foot of the
voltage sensor
To elucidate the specific MTX binding site on KCNQ1, we performed
unbiased in silico docking prediction analysis (SwissDock) using theDe Silva et al., Sci. Adv. 2018;4 : eaav0824 14 November 2018recent cryo-electron microscopy (cryo-EM)–derived KCNQ1 struc-
ture (36). These simulations predicted that MTX binds to R243, which
lies at the foot of S4, the charged helix that senses membrane potential,
abutting the S4-S5 linker. Several poses exhibited hydrogen bond for-
mation between R243 and a hydroxyl group on MTX (Fig. 5, A to C).
In agreement with this prediction, mutation of KCNQ1-R243 to alanine
rendered both KCNQ1 and KCNQ1-KCNE1 complexes completely
insensitive to MTX (10 mM) (Fig. 5D and fig. S6). Docking simula-
tions predicted that CPT1 also binds to KCNQ1-R243 (Fig. 5E). Ac-
cordingly, alanine substitution of KCNQ1-R243 eliminated KCNQ1
(Fig. 5F and fig. S6, E and F) and KCNQ1-KCNE1 (fig. S6, G and H)
sensitivity to CPT1.
Superimposed docking simulations suggested that MTX and CPT1
would compete for the same binding site, rather than being simulta-
neously accommodated in the same binding pocket (Fig. 5G).
Consistent with this prediction, coapplication of both MTX and
CPT1 produced KCNQ1 current augmentation intermediate betweenFig. 3. KCNEs alter MTX effects on KCNQ1. All error bars indicate SEM. (A) Averaged KCNQ1-KCNE1 current traces in response to voltage protocol (upper left inset) in
the absence (control) or presence of 30 mM MTX (n = 5). Dashed line indicates zero current level in this and all following current traces. (B) Mean effects of 30 mM MTX
on KCNQ1 and KCNQ1-KCNE1 raw tail currents at −30 mV after prepulses as indicated [as in (A); n = 5]. (C) Mean instantaneous (inst) current compared to current after 3 s
(both at +40 mV) for KCNQ1-KCNE1 channels in the absence (control) versus presence of MTX (30 mM). **P < 0.01 (n = 5). Left: Raw currents. Right: Instantaneous current/3-s
current. (D) Mean KCNQ1-KCNE1 channel deactivation rate versus voltage in the absence (control) and presence of MTX (30 mM). (E) Mean dose response for effects of MTX on
KCNQ1-KCNE1 current magnitude at −40 mV (n = 5). (F) Averaged KCNQ1-KCNE3 current traces in response to voltage protocol [as in (A)] in the absence (control) or presence
of 30 mM MTX (n = 8). (G) Mean effects of 30 mM MTX on KCNQ1 and KCNQ1-KCNE3 raw tail currents at −30 mV after prepulses as indicated [as in (F); n = 8]. (H) Averaged
KCNQ1-KCNE4 current traces in response to voltage protocol [as in (A)] in the absence (control) or presence of 30 mM MTX (n = 5). (I) Mean effects of 30 mM MTX on KCNQ1
and KCNQ1-KCNE4 raw tail currents at −30 mV after prepulses as indicated [as in (H); n = 5).4 of 9
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 that observed for similar concentrations of either compound alone (Figs.
5,H and I, and fig. S6I). Last, we tested a cocktail of the 10M.oppositifolius
leaf extract components shown in Fig. 1 (see Materials and Methods for
individual concentrations) to determine whether this created synergistic
activation of KCNQ1, but it did not; the cocktail was mildly inhibitory
at depolarized potentials and slightly augmented KCNQ1 activity at hy-
perpolarized potentials (Fig. 5J and fig. S6J). Together, these data strongly
suggest that R243 on the S4-S5 linker of KCNQ1 is the binding site for
both MTX and CPT1 and that these are the primary KCNQ1-activating
components ofM. oppositifolius leaf extract.
MTX also binds to the R243 equivalent in KCNQ2/3
potassium channels
While KCNQ1 channels are essential for human ventricular myocardi-
um repolarization and for the function of a variety of epithelia (8),
KCNQ2/3 channels are best known for generating the muscarinic-
inhibited M current, essential for regulating neuronal excitability
(37–39).We recently found thatMTX also activates KCNQ2/3 chan-
nels in a binding pocket associated with their S5 tryptophan (W236/
W265) but not absolutely requiring it for KCNQ2/3 current augmen-
tation (40). Here, in silico docking prediction and analysis of potential
hydrogen bonding, using a chimeric KCNQ1/KCNQ3model we devel-
oped using the cryo-EM–derived KCNQ1 structure (36, 41), predicted
that similar to the situation in KCNQ1 channels,MTX hydrogen bonds
to the R243 equivalent (R213/R242) at the foot of the voltage sensor of
KCNQ2/3 channels (Fig. 6, A to C). We previously found that KCNQ2De Silva et al., Sci. Adv. 2018;4 : eaav0824 14 November 2018is more sensitive than KCNQ3 to MTX augmentation (40). Here,
heteromeric channels formed from KCNQ2-R213A and wild-type
KCNQ3 exhibited altered voltage dependence of MTX sensitivity,
at least partly because they were less active at baseline than wild-type
KCNQ2/3 at hyperpolarized voltages; at a given voltage, the mutant
channels tended to exhibit a slightly greater MTX-induced shift in
theV0.5 of activation. MTXwas evenmore efficacious upon channels
formed from wild-type KCNQ2 with KCNQ3-R242A. In contrast,
KCNQ2/3 channels carrying both the KCNQ2-R213A and KCNQ3-
R242A substitutions (“RA-RA”) were insensitive to MTX (Fig. 6,
D and E, and figs. S7 to S10). Thus, as for KCNQ1, MTX binds to
R213/R242 on KCNQ2/3 channels, and this is required for current
augmentation.DISCUSSION
Our findings reveal a novel mechanism for pharmacological activation
of Kv channels, involving hydrogen bonding to the arginine lying be-
tween the S4-S5 linker and the voltage sensor. Results of channel voltage
dependence and gating measurements suggest that MTX and CPT1
binding to KCNQ1-R243 stabilizes the channel open state and destabi-
lizes the closed state. Ion channels in general, and arguably potassium
channels in particular, represent an extremely rich vein to tap in terms
of drug targets, yet progress to date has matched neither the need nor
the potential. In this study, we demonstrate one example of how tradi-
tional medicines have much to offer in this regard. By deconstructingFig. 4. Summation of effects of MTX and SMIT1 on KCNQ1 activation. All error bars indicate SEM. (A) Topology of vSGLT, a eukaryotic SLC5A family ortholog
bearing predicted structural similarity to SMIT1. (B) High-resolution structures of KCNQ1 and vSGLT (extracellular view) to illustrate relative sizes. (C) Averaged KCNQ1-
SMIT1 traces in the absence (control) or presence of 30 mM MTX (n = 5). Dashed line indicates zero current level. (D) Mean effects of 30 mM MTX on KCNQ1-SMIT1 raw
tail currents at −30 mV after prepulses as indicated [as in (C); n = 5]. (E) Mean effects of 30 mMMTX on KCNQ1-SMIT1 G/Gmax calculated from tail currents at −30 mV after
prepulses as indicated [as in (C); n = 5]. (F) MTX dose response for mean DV0.5 of activation of KCNQ1-SMIT1 (blue) and KCNQ1 (red) (n = 5 to 7). (G) Comparison of mean
effects of 30 mM MTX on KCNQ1 (red) and KCNQ1-SMIT1 (blue) G/Gmax calculated from tail currents at −30 mV after prepulses as indicated [as in (C); n = 5 to 7].5 of 9
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 the therapeutic leaf extract of M. oppositifolius, we have found both a
novel binding site (KCNQ1-R243) and a novel chemical space (CPT1)
for Kv channel activation.
In rats fedMallotus philippensis extract, oral bioavailability of MTX
has been previously quantified to be >20%, while plasma concentra-
tions have been measured in excess of 2 mg/ml. This high concentra-
tion is aided by the high concentration of MTX in Mallotus, which
was measured to be 21% (w/w) content of a powder prepared from
M. philippensis fruit (42). Plasma levels (2 mg/ml) equate to 4 mM
MTX, at which concentration MTX activates homomeric KCNQ1,
and more efficaciously when in complexes with KCNE1. The levels
that CPT1 reaches in the plasma are not established but would not
necessarily need to be very high, given that we found that CPT1 is a
potent KCNQ1 activator (EC50 of 100 nM).
As the leaf extract has been used for centuries in folk medicine, it
is tempting to assume that toxicity is low, but extensive preclinical
investigations of MTX and CPT1, including toxicity testing, would be
needed before moving to human trials. Like many modern medicines,
MTX is toxic in large doses (43). By the same token, further explora-
tion of derivatives of these two compounds might yield safer and/or
more efficacious compounds better suited for drug trials. Recently,
we found that two components ofM. oppositifolius leaf extract, MTX
and isovaleric acid, synergistically activated heteromeric KCNQ2/3
channels, thus uncovering the molecular mechanism behind the anti-
convulsant properties of this widely used African traditional medi-
cine (40). KCNQ1 lacks the S5 tryptophan, KCNQ2-W235, requiredDe Silva et al., Sci. Adv. 2018;4 : eaav0824 14 November 2018for activation by isovaleric acid, and therefore is insensitive to it.
However, our new data show that MTX sensitivity is shared between
these KCNQs because the R243 equivalent is conserved among
them. Our other recent work suggests that the S5 tryptophan is ab-
sent from the nonneuronal KCNQ1 because KCNQ3-W265 and its
equivalent evolved in a neuronal progenitor KCNQ subunit to confer
sensitivity to neuronal metabolites/neurotransmitters including
g-aminobutyric acid and g-amino-b-hydroxybutyric acid (41). As
more of the picture becomes clear of KCNQ pharmacology, with re-
spect to endogenous and exogenous natural compounds, we will be
better able to predict and develop specificity, synergy, safety, and ef-
ficacy for polypharmaceutical modulation of this influential Kv chan-
nel family.
There are many other species in the genusMallotus, ranging across
Africa, Asia, Afghanistan, and Australia. While some are currently pri-
marily in ornamental use (e.g.,Mallotus japonica), others are also used
for dyes andmedicinal purposes.Mallotus philippinensis, widely distrib-
uted along the east coast of Australia and in the Himalayas, bears glan-
dular hairs from its fruit capsule that yieldKamala, a red powder used as
an antihelminthic and effective in animalmodels of woundhealing (44).
Some, includingM.oppositifolius, theGhanian shrubMallotus atrovirens,
and the Sri Lankan shrubMallotus fuscescens, are on the International
Union for Conservation of Nature Red List of Threatened Species,
underlining the importance of discovering therapeutic uses of the con-
stituents of these plants and protecting them by safeguarding their
natural environments.Fig. 5. MTX and CPT1 compete for binding to R243 on the KCNQ1 S4-S5 linker. All error bars indicate SEM. (A) KCNQ1 topology (two of four subunits shown)
indicating the position of R243 on the S4-S5 linker. (B) SwissDock result showing predicted binding of MTX to KCNQ1 via hydrogen bonding (green line) to R243. (C) Close-up
of docking shown in (B). (D) Mean current augmentation by MTX versus voltage of wild-type and KCNQ1-R243A and KCNQ1-KCNE1 channels (n = 5 to 8). (E) SwissDock result
showing predicted binding of CPT1 to KCNQ1-R243. (F) Mean current augmentation by CPT1 versus voltage of wild-type (from Fig. 2) and KCNQ1-R243A channels (n = 10).
(G) SwissDock result showing predicted binding pose overlap in KCNQ1 of MTX and CPT1. (H) Mean effects of 30 mMMTX + 10 mM CPT1 on KCNQ1 raw tail currents (upper)
and G/Gmax (lower) at −30 mV after prepulses as indicated (n = 5). (I) Mean current augmentation versus voltage of KCNQ1 by 30 mM MTX + 10 mM CPT1 (blue) [from (H)]
compared to effects for MTX alone (red) or CPT1 alone (orange) (from Fig. 2) (n = 4 to 7). (J) Mean effects of M. oppositifolius leaf extract cocktail on KCNQ1 raw tail currents
(upper) and G/Gmax (lower) at −30 mV after prepulses as indicated (n = 6).6 of 9
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 MATERIALS AND METHODS
Channel subunit cRNA preparation and X. laevis
oocyte injection
Complementary RNA (cRNA) transcripts encoding human KCNQ1,
KCNQ2, KCNQ3, KCNE1, KCNE3, KCNE4, or SMIT1were generatedDe Silva et al., Sci. Adv. 2018;4 : eaav0824 14 November 2018by in vitro transcription using a T7 polymerase mMessage mMachine
kit (Thermo Fisher Scientific), after vector linearization, from com-
plementary DNA (cDNA) subcloned into plasmids incorporating
X. laevis b-globin 5′ and 3′ untranslated regions flanking the coding
region to enhance translation and cRNA stability. cRNAwas quantifiedFig. 6. MTX binds to the R243 equivalents on KCNQ2/3 channels. All error bars indicate SEM. (A) KCNQ2/3 topology (two of four subunits shown) indicating the
position of R243 equivalents (R213/242) and of KCNQ2-W236/KCNQ3-W265 (orange pentagons). (B) SwissDock result showing predicted binding of MTX to KCNQ3 via hy-
drogen bonding (green line) to R242. (C) Close-up of docking shown in (B). (D) Left: Averaged wild-type and arginine mutant KCNQ2/3 traces as indicated in the absence
(control) or presence of 30 mM MTX. Dashed line indicates zero current level. Mean tail currents (center). Mean G/Gmax (right) from traces as in left (n = 5 to 6). (E) Analysis of
MTX effects recorded from wild-type and mutant KCNQ2/3 traces as in (D). Left: Current fold change in response to MTX (30 mM). Center: MTX dose responses for channel V0.5
activation shifts. Right: MTX dose responses for channel current augmentation at −60 mV (n = 5 to 6).7 of 9
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 by spectrophotometry. Mutant cDNAs were generated by site-directed
mutagenesis using a QuikChange kit according to the manufacturer’s
protocol (Agilent, Santa Clara, CA) and corresponding cRNAs prepared
as above. Commercially sourced, defolliculated stages V and VIX. laevis
oocytes (Ecocyte Bioscience, Austin, TX) were injected with Kv channel
a subunit cRNAs (10 ng total per oocyte). Oocytes were incubated at
16°C in Barth’s saline solution (Ecocyte Bioscience) containing penicil-
lin and streptomycin, with daily washing for 2 to 5 days before two-
electrode voltage-clamp (TEVC) recording.
Two-electrode voltage clamp
TEVC recording was performed at room temperature with an OC-725C
amplifier (Warner Instruments, Hamden, CT) and pCLAMP 8 software
(Molecular Devices, Sunnyvale, CA) 2 to 5 days after cRNA injection as
described in the section above. Oocytes were placed in a small-volume
oocyte bath (Warner) and viewed with a dissection microscope. Chem-
icals were sourced from Sigma-Aldrich. Bath solution was composed of
96mMNaCl, 4 mMKCl, 1 mMMgCl2, 1mMCaCl2, and 10mMHepes
(pH 7.6). Isovaleric acid, 2-mercaptophenol, 1-heptene, and CPT1 were
stored at 4°C as 5 mM stocks in Ringer’s solution. MTX (dimethyl sulf-
oxide), sorbic acid (ethanol), and glutaconic acid (molecular grade H2O)
were stored at−20°C as 1M stocks.Oleamidewas stored as a 1mMstock
in ethanol at 4°C. Palmitic acid was conjugated with bovine serum albu-
min as a 1 mM stock and stored at −20°C, as previously described (40).
All compounds were diluted to working concentrations each experi-
mental day. The leaf extract cocktail was composed of 10 mM MTX,
10 mMCPT1, 50 mMpalmitic acid, 50 mM isovaleric acid, 50 mMvaleric
acid, 50mMglutaconic acid, 50mMsorbic acid, 50 mM1-heptene, 50mM
2-mercaptophenol, and 50 mM oleamide.
Compounds were introduced to the recording bath via gravity
perfusion at a constant flow of 1 ml/min for 3 min prior to recording.
Pipettes were of 1 to 2 megohm resistance when filled with 3 M KCl.
Currents were recorded in response to pulses between −80 and +40 mV
at 20-mV intervals, or a single pulse to +40 mV from a holding poten-
tial of −80 mV to yield current-voltage relationships, current magni-
tude, and for quantifying activation rate. TEVC data analysis was
performed with Clampfit (Molecular Devices) and GraphPad Prism
software (GraphPad, San Diego, CA, USA). Values are stated as
mean ± SEM. Normalized tail currents were plotted versus prepulse
voltage and fitted with a single Boltzmann function
g ¼ ðA1  A2Þ
1þ exp V1
2
 V
h in o
y þ A2
ð1Þ
where g is the normalized tail conductance, A1 is the initial value at
−∞, A2 is the final value at +∞, V1/2 is the half-maximal voltage of
activation, and Vs is the slope factor. Activation and deactivation ki-
netics were fitted with single exponential functions.
Chemical structures, in silico docking, and sequence analyses
Chemical structures and electrostatic surface potentials (range, −0.1
to 0.1) were plotted using Jmol, an open-source Java viewer for chem-
ical structures in three dimension (http://jmol.org/). Unguided
docking of MTX and CPT1 to predict binding sites was performed
using the X. laevis KCNQ1 cryo-EM structure (36) and a KCNQ1-
KCNQ3 chimeric model based on it (41) using SwissDock (45) with
CHARMM (Chemistry at HARvard Macromolecular Mechanics)
force fields (46), as previously described (47).De Silva et al., Sci. Adv. 2018;4 : eaav0824 14 November 2018Statistical analysis
All values are expressed as mean ± SEM. All P values were two sided.
Statistical significance was defined as P < 0.05.SUPPLEMENTARY MATERIALS
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Fig. S1. Effects of CPT1 on KCNQ1 channels.
Fig. S2. Effects of MTX on KCNQ1 channels.
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Fig. S4. Effects of MTX on KCNQ1/SMIT1 channels.
Fig. S5. Interaction of MTX with permeant ions and UCL2077.
Fig. S6. MTX and CPT1 bind to R243 on the KCNQ1 S4-S5 linker.
Fig. S7. Effects of MTX on KCNQ2/KCNQ3 channels.
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